ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,012.28
      -1.46%
      US Tech 100
      20,596.80
      0.14%
      Dow Jones
      44,713.58
      0.65%
      Brent Oil
      76.815
      0.71%
      Bitcoin
      102,691.09
      0.62%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC

      6. Defence Therapeutics Inc (QB) (DTCFF) Quote

      Defence Therapeutics Inc (QB)

      Defence Therapeutics Inc (QB) (DTCFF)

      USOTC
      0.70
      0.00
      (0.00%)
      Closed January 28 4:00PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      0.70
      Bid
      0.4942
      Ask
      0.9538
      Volume
      -
      0.00 Day's Range 0.00
      0.2732 52 Week Range 1.738
      Market Cap
      33.355M
      Previous Close
      0.70
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      24,443
      Shares Outstanding
      47,650,370
      Dividend Yield
      -
      PE Ratio
      -2.53
      Earnings Per Share (EPS)
      -0.28
      Revenue
      -
      Net Profit
      -13.19M

      About Defence Therapeutics Inc (QB)

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.defencetherapeutics.com
      Headquarters
      Vancouver, British Columbia, Can
      Founded
      -
      Defence Therapeutics Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker DTCFF. The last closing price for Defence Therapeutics (QB) was $0.70. Over the last year, Defence Therapeutics (QB) shares have traded in a share price range of $ 0.2732 to $ 1.738.

      Defence Therapeutics (QB) currently has 47,650,370 shares outstanding. The market capitalization of Defence Therapeutics (QB) is $33.36 million. Defence Therapeutics (QB) has a price to earnings ratio (PE ratio) of -2.53.

      Ask ADVFN Intelligence (AI)

      DTCFF Latest News

      More News

      FeaturedLaFleur Minerals Provides Updates on Exploration at Swanson Gold Deposit and Plans to Restart of Beacon Gold Mill

      22 hours ago

      DEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

       DEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER  Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...

      February 16 2022
      InvestorsHub NewsWire

      Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

        Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9   Vancouver, BC, Canada, January 26th...

      January 26 2022
      InvestorsHub NewsWire

      DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

      Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...

      November 30 2021
      InvestorsHub NewsWire

      DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

      DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER   Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...

      November 23 2021
      InvestorsHub NewsWire

      DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

       DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...

      November 09 2021
      InvestorsHub NewsWire

      VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

        VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS   Vancouver, BC, Canada, November...

      November 03 2021
      InvestorsHub NewsWire

      DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

        DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER   Vancouver, BC, Canada, October 13th...

      October 13 2021
      InvestorsHub NewsWire

      DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

          DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...

      October 06 2021
      InvestorsHub NewsWire

      DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

       DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...

      September 29 2021
      InvestorsHub NewsWire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.096716.02850986240.60330.71940.5401748470.69055524CS
      40.2555.55555555560.450.71940.415479490.66396478CS
      120.2952872.95908282270.404720.71940.2732244430.65948543CS
      260.133623.58757062150.56640.71940.2732123100.65136459CS
      52-0.83-54.24836601311.531.7380.273252700.6765157CS
      156-2.8335-80.18961369753.53354.470.273227121.03442838CS
      260-1.8-722.56.40780.273224641.65840282CS

      DTCFF - Frequently Asked Questions (FAQ)

      What is the current Defence Therapeutics (QB) share price?
      The current share price of Defence Therapeutics (QB) is $ 0.70
      How many Defence Therapeutics (QB) shares are in issue?
      Defence Therapeutics (QB) has 47,650,370 shares in issue
      What is the market cap of Defence Therapeutics (QB)?
      The market capitalisation of Defence Therapeutics (QB) is USD 33.36M
      What is the 1 year trading range for Defence Therapeutics (QB) share price?
      Defence Therapeutics (QB) has traded in the range of $ 0.2732 to $ 1.738 during the past year
      What is the PE ratio of Defence Therapeutics (QB)?
      The price to earnings ratio of Defence Therapeutics (QB) is -2.53
      What is the reporting currency for Defence Therapeutics (QB)?
      Defence Therapeutics (QB) reports financial results in CAD
      What is the latest annual profit for Defence Therapeutics (QB)?
      The latest annual profit of Defence Therapeutics (QB) is CAD -13.19M
      What is the registered address of Defence Therapeutics (QB)?
      The registered address for Defence Therapeutics (QB) is 1680 - 200 BURRARD STREET, VANCOUVER, BRITISH COLUMBIA, V6C 3L6
      What is the Defence Therapeutics (QB) website address?
      The website address for Defence Therapeutics (QB) is www.defencetherapeutics.com
      Which industry sector does Defence Therapeutics (QB) operate in?
      Defence Therapeutics (QB) operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AABVFAberdeen International Inc (PK)
      $ 0.015
      (0.00%)
      		0
      AABKFAareal Bank AG (PK)
      $ 0.00
      (0.00%)
      		0
      AABBAsia Broadband Inc (PK)
      $ 0.02695
      (0.00%)
      		0
      AAALYAareal Bank AG (PK)
      $ 34.65
      (0.00%)
      		0
      AAAIFAlternative Investment Trust (PK)
      $ 0.55
      (0.00%)
      		0
      AABVFAberdeen International Inc (PK)
      $ 0.015
      (0.00%)
      		0
      AABKFAareal Bank AG (PK)
      $ 0.00
      (0.00%)
      		0
      AABBAsia Broadband Inc (PK)
      $ 0.02695
      (0.00%)
      		0
      AAALYAareal Bank AG (PK)
      $ 34.65
      (0.00%)
      		0
      AAAIFAlternative Investment Trust (PK)
      $ 0.55
      (0.00%)
      		0
      AABVFAberdeen International Inc (PK)
      $ 0.015
      (0.00%)
      		0
      AABKFAareal Bank AG (PK)
      $ 0.00
      (0.00%)
      		0
      AABBAsia Broadband Inc (PK)
      $ 0.02695
      (0.00%)
      		0
      AAALYAareal Bank AG (PK)
      $ 34.65
      (0.00%)
      		0
      AAAIFAlternative Investment Trust (PK)
      $ 0.55
      (0.00%)
      		0

      DTCFF Discussion

      View Posts
      Man6677 Man6677 3 years ago
      Why are there no trades here ?

      Thank you !

      Great news today !
      👍️0
      newspopper newspopper 3 years ago
      Get in KITL .08-.10 news will be poppin
      👍️0
      newspopper newspopper 3 years ago
      Need more volume for Poppin action
      👍️0
      newspopper newspopper 3 years ago
      Looking for FDA Poppin news
      👍️0
      newspopper newspopper 3 years ago
      KITL news going to be poppin
      👍️0
      GOLDBUFFALO GOLDBUFFALO 3 years ago
      Seems to be a very interesting stock.
      👍️0

      Your Recent History

      USOTC
      DTCFF
      Defence Therapeutics (QB)
      BIT
      S29259
      Societe Generale Effekten
      BIT
      P19CA9
      BNP Paribas Issuance
      BIT
      I10451
      IT0005615932 20250303 6.8
      BOV
      T1AM34
      Atlassian
      BIT
      NSCIT2125309
      African Development Bank
      BOV
      A5SJ6L
      Agropecuaria Sao Joao Do... PNB
      BOV
      MERC1
      MERCANTIL DO BRASIL ON
      BIT
      UI183B
      Unicredit Bank
      BIT
      NSCIT2524147
      International Finance
      BIT
      P1NIP5
      BNP Paribas Issuance
      BIT
      XUTC
      Xtrackers MSCI USA Infor...
      BIT
      ALFO
      Alfonsino
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads